Point-of-care testing (POCT) is the fastest growing segment of a US$30 billion worldwide market. "Errors" in the testing process, as well as medical data interpretation and treatment associated with POCT, are recognized as leading to major compromises of patient safety. In today's environment, most testing errors (pre-analytical, analytical and post-analytical) can be virtually eliminated by proper design of testing systems. We cite examples of two systems that have made exceptional progress in this respect. It has been recently suggested that the basic errors associated with the testing process are amplified in the POC setting. Two of the amplifiers - incoherent regulations and failure of clinician/caregivers to respond appropriately to POCT results - lead us to recognize additional changes in today's POCT environment. The first is a willingness of manufacturers, not laboratories, to take responsibility for the quality of test results - an outgrowth of an industrial philosophy called autonomation. The second is a need to substantially modify the clinician/caregiver test utilization paradigm to take full advantage of POCT results, available on site in real time. Both have already begun to take place.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1515/CCLM.2007.164 | DOI Listing |
Nat Commun
January 2025
CAS Key Laboratory of Urban Pollutant Conversion, Department of Environmental Science and Engineering, University of Science and Technology of China, 230026, Hefei, China.
The CRISPR-based detection methods have been widely applied, yet they remain limited by the non-universal nature of one-pot diagnostic approaches. Here, we report a universal one-pot fluorescent method for the detection of epidemic pathogens, delivering results within 15-20 min. This method uses heparin sodium to precisely tunes the cis-cleavage capability of Cas12 via interference with the Cas12a-crRNA binding process, thereby generating significant fluorescence due to the accumulation of isothermal amplification products.
View Article and Find Full Text PDFAnal Biochem
January 2025
Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160062, India. Electronic address:
Aptamers, discovered in the 1990s, have marked a significant milestone in the fields of therapeutics and diagnostics. This review provides a comprehensive survey of aptamers, focusing on their diagnostic applications. It especially encapsulates a decade of aptamer, encompassing research, patents, and market trends.
View Article and Find Full Text PDFTalanta
January 2025
The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Cysteamine (CA) serves as a cystine-depleting agent employed in the management of cystinosis and a range of other medical conditions. Monitoring blood CA levels at the point of care is imperative due to the risk of toxicity associated with elevated CA dosages. An additional significant challenge is presented by the intricate composition of human plasma and the presence of various interfering biological thiols, which possess similar structures or properties.
View Article and Find Full Text PDFAust Crit Care
January 2025
Perioperative Care Program, Perioperative Medicine Team, Telethon Kids Institute, Perth, WA, Australia; Division of Emergency Medicine, Anaesthesia and Pain Medicine, Medical School, The University of Western Australia, Perth, WA, Australia; Institute for Paediatric Perioperative Excellence, The University of Western Australia, Perth, WA, Australia.
Background: Personal protective equipment is essential to protect healthcare workers when exposed to aerosol-generating procedures in patients with airborne respiratory pathogens.
Aim: This study aimed to provide information regarding the level of airborne protection offered to nursing staff and other healthcare workers in Australian and New Zealand intensive care units (ICUs) 1 year into the coronavirus disease 2019 pandemic.
Methods: In this cross-sectional survey, ICUs in Australia and New Zealand were asked to participate in the Australian and New Zealand Intensive Care Society Clinical Trials Group Point Prevalence Program in June 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!